secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034667
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus reports FY2023 net loss $43.6M, cash $389M; Phase 2 gMG trial initiated
--------------------------------------------------------------------------------

- FY2023 net loss $43.6M ($8.45/share), R&D $32.8M, G&A $18.2M.
- Pro forma cash $389M (including $216M net from Jan 2024 PIPE); runway to 2H 2027.
- Phase 2 MaGic gMG trial initiated Feb 2024; top-line data expected 2H 2025.
- Phase 2 trials planned: MMN (Q2 2024) and CIDP (2H 2024).
- Jeffrey Stavenhagen appointed CSO in Nov 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/0000950170-24-034667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/dnth-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer